INTRODUCTION Nanoparticles may serve as a promising means to deliver novel therapeutics to the myocardium following myocardial infarction. We assessed whether lipid-based liposomal nanoparticles specifically target injured myocardium following intravenous injection.
INTRODUCTION Nanoparticles may serve as a promising means to deliver novel therapeutics to the myocardium following myocardial infarction. We assessed whether lipid-based liposomal nanoparticles specifically target injured myocardium following intravenous injection.
METHODS CD1 male mice that underwent LAD ligation surgery with 45 minutes of ischemia followed by reperfusion (I/R) and then received tail-vein injection 24 hours following surgery with either Gd-DTPA labeled, fluorescent NBD-labeled liposomes (n¼7) or a saline vehicle control (n¼7). The hearts were harvested 24 hours later and underwent T1 and T2-weighted ex vivo MR imaging using a 7 Tesla Bruker magnet. The hearts were the sectioned for immunohistochemistry and also optical fluorescent imaging using an IVIS imaging system.
RESULTS
The mean size of the liposomes was 100 nm by dynamic light scattering. T1-weighted imaging demonstrated a significant increase in signal intensity in the LAD territory vs the posterior wall with liposomes compared with control (41 AE10% vs 9AE 2%, p¼0.009). Optical imaging demonstrated significant increase in the LAD territory vs the posterior wall for animals that received liposomes compared with those that received control (163AE31% vs 13AE14%, p¼0.001). The Figure shows T1-weighted MR images and optical images below. Fluorescent microscopy demonstrated the presence of green fluorescence consistent with NBD-labeled liposomes within the infarct area of hearts from mice that received liposomes while there was no green fluorescence in the hearts of mice that received injection of saline control.
CONCLUSIONS Following a murine model of MI, liposomes traffic to the heart and preferentially home to regions of myocardial injury. These liposomes can be loaded with therapeutic agents to deliver novel agents directly to regions of myocardial injury. BACKGROUND A confluent endothelium is needed to reduce thrombosis in vascular grafts, including EVAR stent-grafts. A pilot study was designed to assess the tissue formation and cellular response to an endovascular stent-graft containing a bioabsorbable graft material designed to treat aneurysms through endovascular tissue regeneration. The objective of the study was to determine the in vivo response of the graft material in an AAA model. METHODS A peritoneal patch was used to form an AAA in swine for 2 weeks then treated with the bioabsorbable stent-graft (n¼7). The stent-graft consisted of a synthetic polymer graft material sutured to a stent (Megalink, Guidant, USA). The stentgraft was delivered endovascularly using an 11F sheath with a dilation catheter (Powerflex P3, Cordis, USA). After treatment for 28 days, the animals were sacrificed and the tissue was examined through both gross and microscopic histology to determine the presence of endothelial cells (CD-31 antibody), smooth muscle cells (SM a-actin antibody), collagen (Masson's Trichrome) and any adverse tissue responses (H&E). Physical attachment of the graft to the vessel and gross appearance of the lumen surface were also noted.
RESULTS The stent-grafts placed endovascularly demonstrated no evidence of blood flow into the aneurysmal sac upon deployment, based on angiography and ultrasound imaging. During the course of the study, no endoleaks were observed in the treated animals. Upon gross examination after sacrifice at 28 days, the graft material appeared well adhered to the aorta with a shiny, white appearance on the lumen surface. No evidence of thrombi was noted. The graft demonstrated a confluent endothelial lining as evidenced by histologic staining for CD-31 antibody which positively stained a single layer of cells on the lumen surface. The new endothelium was supported by a thin neointima consisting of collagen. In addition, the SM a-actin antibody stain indicated the presence of smooth muscle cells on the abluminal portion of the graft with cells penetrating the porous graft material. No significant adverse tissue response was noted. The graft material was integrated with the vessel wall and grossly intact without any defects or degradation.
CONCLUSIONS A stent-graft containing a bioabsorbable graft material was successfully deployed endovascularly in a surgical swine model. The results of our pilot study suggest that aneurysms may be treated using an appropriate bioabsorbable material for endovascular tissue regeneration. 
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RESULTS
Of the 8 studies included in the analysis, 6 were non-randomized and 2 were randomized against bare-metal stents (BMS). A total of 1,037 patients were studied, with follow-up ranging from 1 month to 5 years. PES, SES and everolimuseluting stents (EES) were studied. Myocardial infarction at one year was highest in PES vs. SES and EES: 4.2% vs. 3.4% and 1.5%. Target vessel revascularization at one year was highest in PES vs. SES and EES: 13.8% vs. 5.7% and 8.8%. Death rate was highest in PES at 4.2% vs. SES and EES (3.4% and 1.5%). Mean late lumen loss for PES, SES, and EES was 0.28AE0.11 mm, 0.15AE0.11 mm, and 0.16AE0.41 mm at 9 months to 1 year. Mean diameter stenosis for PES, SES and EES was 34.7AE4.2%, 29.5AE6.2%, and 20.9AE22.5%. Mean binary stenosis for PES, SES and EES was 26.9AE7.8%, 10.4AE6.7%, and 9.6% respectively. No 2.25 mm specific data was available for zotarolimus eluting stents, which was reported in combination with larger stent sizes.
CONCLUSION Our composite data suggest that 2.25-mm SES and EES have superior clinical and angiographic outcomes compared with 2.25-mm PES, which has been shown to be superior to BMS in a randomized controlled study. Given the unique theoretical challenges posed by small vessel PCI, the overall lack of randomized data in this cohort needs to be addressed with future studies evaluating 2.25 mm stents in next-generation DES.
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